Snipd home pageGet the app
public
JAMA Clinical Reviews chevron_right

Monoclonal Antibodies Targeting Amyloid for Alzheimer Disease

whatshot 21 snips
Aug 3, 2023
Guest
Gil D. Rabinovici
28:48
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
1
Introduction
00:00 • 3min
chevron_right
2
The Evolution of Amyloid Antibodies
03:24 • 4min
chevron_right
3
Dannamab and the Trailblazer All's 2 Trial
07:08 • 3min
chevron_right
4
The Clinical Meaningfulness of DINANIMAB
10:34 • 4min
chevron_right
5
The Risks of ARIA-E in DINANAMAP
14:17 • 4min
chevron_right
6
The Potential Use of Alzheimer's Drugs in the Clinics
18:45 • 6min
chevron_right
7
The Trial of Monoclonal Antibodies
24:22 • 2min
chevron_right
8
The Prospects for DANANIMAB as a Treatment for Alzheimer's Disease
25:54 • 3min
chevron_right

In this interview, dementia expert Gil D. Rabinovici, MD, discusses monoclonal antibodies that target beta-amyloid–-including a recent phase 3 trial of donanemab published in JAMA-–and reviews considerations for their use in patients with Alzheimer disease. Related Content:

  • Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease
  • Donanemab in Early Symptomatic Alzheimer Disease
HomeTop podcastsPopular guests